[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587198":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":23,"locations":29,"responsibleParty":48,"collaborators":50,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":10,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":10,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Red Nucleus Enterprise Solutions, LLC","INDUSTRY",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Subsample A - Caregivers",null,"Caregivers of individuals with DMD treated with givinostat for at least 2 years",{"label":13,"type":10,"description":14,"interventionNames":10},"Subsample A - Patients","Patients with DMD treated with givinostat for at least 2 years",{"label":16,"type":10,"description":17,"interventionNames":10},"Subsample B - Caregivers","Caregivers of individuals with DMD never treated with givinostat",[19],{"name":20,"affiliation":21,"role":22},"Mindy Leffler, M.Ed.","Red Nucleus Solutions","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Mary Hubbard","CONTACT","904-541-9326","mhubbard@rednucleus.com",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Red Nucleus","RECRUITING","Yardley","Pennsylvania","19067","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-74.846,40.24566,{"lat":42,"lon":41},[45,46],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},{"name":47,"role":22,"phone":10,"phoneExt":10,"email":10},"Mindy Leffler",{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[51],{"name":52,"class":6},"Italfarmaco S.A","100587198","dmd-voice-qualitative-interviews-with-patients-and-caregivers-100587198",false,"NCT06925269","DMD Voice: Qualitative Interviews With Patients and Caregivers","Duchenne Muscular Dystrophy Quality of Life: Qualitative Interviews With Patients and Caregivers","Inclusion Criteria:\n\nSubsample A - Patients\n\nEligible participants for Subsample A must:\n\n* Have been treated with Givinostat for at least 2 years\n* Be at least 10 years of age with signed consent of a parent or legal guardian\n* Be currently taking givinostat\n* Willing and able to participate in a video and\u002For audio recorded interview\n\nSubsample A - Caregivers\n\nEligible caregivers for Subsample A must:\n\n* Be a parent or legal guardian of an individual with DMD that has been taking givinostat for at least two years\n* Willing and able to participate in a video and\u002For audio recorded interview\n\nSubsample B - Caregivers\n\nEligible caregivers for Subsample B must:\n\n* Provide care to an individual with DMD who is unable to raise their hands above their head as confirmed by the caregiver\n* Reside in the United States or Canada\n* Able to read, speak, and understand English\n* Willing and able to participate in a video and\u002For audio recorded interview Have access to a stable internet connection\n\nExclusion Criteria:\n\n\\-","MALE","10 Years",{"count":63,"type":64},68,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to understand DMD functional losses or abilities and their association with independence and quality of life from the perspective of individuals with DMD and\u002For and their caregivers.\n\nThis is a qualitative interview study in which individuals with DMD and\u002For their caregivers will be asked to participate in a semi-structured, approximately 60- minute interview. Interviews will focus on functional abilities and independence. Caregivers and boys with DMD will be interviewed. This study includes no treatment nor intervention; however, some participants are being treated by a drug that is approved in the U.S. and the U.K. and under investigation in other geographies.",[68],"Duchenne Muscular Dystrophy (DMD)",[70,71],"Duchenne","givinostat","2025-04-29",{"date":74,"type":75},"2025-04-30","ACTUAL",{"date":77,"type":75},"2025-03-31",{"date":79,"type":64},"2026-12",{"name":5,"class":6},1]